Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects

Pharmazie

Volumn 68, Issue 4, 2013, Pages 257-260

  Zheng, T ^a   Su, C H ^a   Zhao, J ^b   Zhang, X J ^b   Zhang, T Y ^a   Zhang, L R ^b   Kan, Q C ^b   Zhang, S J ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DESACETYL DILTIAZEM; DILTIAZEM; DRUG METABOLITE; N DESMETHYL DILTIAZEM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CYTOCHROME P450 2D6 GENE; CYTOCHROME P450 3A5 GENE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SINGLE DRUG DOSE;

ADULT; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; CHINA; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DILTIAZEM; DNA; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84876249926     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2783     Document Type: Article

References (18)

1. Höglund P, Nilsson LG (1989) Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther Drug Monit 11: 543.
2. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290: 1116-1125.
3. Jose de Leon, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
4. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenet Genomics 13: 461-472.
5. Luo X, Li X, Hu Z, Cheng Z (2009) Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 30: 1323-1329.
6. Molden E, Johansen PW, Bøe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G (2002) Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 72: 333-342.
7. Qin S, Shen L, Zhang A, Xie J, Shen W, Chen L, Tang J, Xiong Y, Yang L, Shi Y, Feng G, He L, Xing Q (2008) Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 92: 152-158.
8. Shih PS, Huang JD (2002) Pharmacokinetics of midazolam and 1'- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30: 1491-1496.
9. van derWeide J, Steijns L (1999) Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 36: 722-729.
10. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Pharmacodyn 24: 475-490.
11. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30: 883-891.
12. Williams JA, Cook J, Hurst SI (2003) A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31: 1526-1531.
13. Wojnowski L, Kamdem LK (2006) Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2: 171-182.
14. Wrighton SA, Ring BJ,Watkins PB,VandenBrandenM(1989) Identification of a polymorphically expressed member of the human cytochrome P- 450III family. Mol Pharmacol 36: 97-105.
15. Xu Y, Sun Y, Yao L, Shi L,Wu Y, Ouyang T, Li J,Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y (2008) Association between CYP2D610 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19: 1423-1429.
16. Yamamoto T, Kubota T, Ozeki T, Sawada M, Yokota S-i, Yamada Y, Kumagai Y, Iga T (2005) Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clin Chim Acta 362: 147-154.
17. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T (2004a) CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19: 120-129.
18. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T (2004b) CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19: 120.